ACTIVITY OF CHIMERIC ANTIBODIES TO CD20 ON B LYMPHOCYTES IN PATIENT WITH SEVERE SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS

Case report about early debut and severe clinical course of system type of juvenile rheumatoid arthritis, refractory to treatment with classic immunosuppressive agents and blocker of tumor necrosis factor is presented in this article. A successful application of chimeric antibodies to cd20+ b-lymphocytes rituximab in dose 375 mg/m2 of surface of body weekly intravenously are described. Rituximab infusions were carried out during 4 weeks. Patient took 2 treatment courses of rituximab. Extra articular symptoms of disease and acute inflammatory lesions in joints were stopped by 8 week. Range of motions in affected joints was increased. A new attack of disease developed in 22 weeks after acute respiratory infection. Increase of level of CD 19+ and CD 20+ b-lymphocytes in peripheral blood was the reason of repeated treatment course, including rituximab in the same scheme. Treatment initiated the development of clinical and laboratory remission, duration of it was equal 22 weeks.Key words: children, juvenile rheumatoid arthritis, rituximab

EXPERIENCE OF CLINICAL USE OF RITUXIMAB IN PATIENT WITH SYSTEMIC JUVENILE ARTHRITIS (A CASE REPORT)

The case of early onset and severe course of systemic juvenile rheumatoid arthritis refractory to classic immunosuppressive agents and blockers of tumor necrosis factor (TNF) is presented in this article. Successful clinical use of biological agent rituximab was described. extraarticular symptoms of disease were stopped by 6 week of treatment, and acute inflammatory alteration of articulations was reduced by 16 week, the range of motions was completely restored. This case report demonstrates high activity of rituximab. A clinical and laboratory remission of disease in patient with severe course of systemic juvenile rheumatoid arthritis continues for a 32 weeks.Key words: children, juvenile rheumatoid arthritis, rituximab.</strong

EXPERIENCE OF CLINICAL USE OF RITUXIMAB IN PATIENT WITH SYSTEMIC JUVENILE ARTHRITIS (A CASE REPORT)

The case of early onset and severe course of systemic juvenile rheumatoid arthritis refractory to classic immunosuppressive agents and blockers of tumor necrosis factor (TNF) is presented in this article. Successful clinical use of biological agent rituximab was described. extraarticular symptoms of disease were stopped by 6 week of treatment, and acute inflammatory alteration of articulations was reduced by 16 week, the range of motions was completely restored. This case report demonstrates high activity of rituximab. A clinical and laboratory remission of disease in patient with severe course of systemic juvenile rheumatoid arthritis continues for a 32 weeks.Key words: children, juvenile rheumatoid arthritis, rituximab

EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS

The article gives a case report on patient with severe systemic type of juvenile arthritis, refractory to treatment with classical immuno suppressants and blocker of tumor necrotizing factor Successive application of biological agent — rituximab was described. In 9 weeks, extra articular symptoms of disease and acute inflammatory lesions in joints were stopped, and functional activity of child increased. Presented case report demonstrates high effectiveness of rituximab: patient with severe systemic type of juvenile arthritis has clinical and laboratory remission of disease during 12 months.Key words: children, juvenile rheumatoid arthritis, rituximab.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(3):132-138